Neose Receives Research Milestone Payment from Novo Nordisk.

HORSHAM, Pa. -- Neose Technologies, Inc. (Nasdaq-GM:NTEC) today announced that it received a research milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement entered into in November 2003 for the use of Neose's GlycoPEGylation(TM) technology to develop next-generation versions of Factors VIII and IX. The Company is also working with Novo Nordisk to develop a next-generation version of Factor VIIa.

"We are pleased with the overall success of our collaboration with Novo Nordisk," said George J. Vergis, Ph.D., Neose president and chief executive officer. "Novo continues to be an ideal partner for Neose, providing significant clinical development expertise and a strong commitment to broadening their haemostasis product portfolio that should prove invaluable in the success of long-acting Factors VIIa, VIII and IX."

About Coagulation Factors VIII and IX

Factor VIII products are used in the treatment of Hemophilia A. People with Hemophilia A, often called classic hemophilia, do not produce adequate amounts of Factor VIII, which is necessary for the blood to clot effectively. According to the National Hemophilia Foundation, Hemophilia A is the most common type of hemophilia, occurring in one in 5,000 to 10,000 male births. The worldwide market for recombinant Factor VIII products was approximately $2 billion in 2005

Factor IX products are used in the treatment of Hemophilia B. Hemophilia B, also known as Christmas Disease, is caused by a deficiency of a blood plasma protein called factor IX that affects the clotting property of blood. According to the National Hemophilia Foundation, Hemophilia B is the second most common type of hemophilia, occurring in about one in 25,000 male births. The worldwide market for recombinant Factor IX was approximately $350 million in 2005.

About Novo Nordisk A/S

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk has more than 22,500 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $14 billion. Neose expects to commence Phase II for NE-180 in a Western European country in the fourth quarter of 2006. Neose expects that its partner for GlycoPEG-GCSF, BioGenerix AG, will commence Phase I in a Western European country in the third quarter of 2006.

For more information, please visit www.neose.com.

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the collaboration will not continue or will not be successful, or that long-acting versions of Factors VIIa, VIII and IX will not be successfully developed. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose's Annual Report on Form 10-K for the year ended December 31, 2005, entitled "Factors Affecting the Company's Prospects" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.